BRPI0821115A2 - Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto - Google Patents

Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Info

Publication number
BRPI0821115A2
BRPI0821115A2 BRPI0821115-9A BRPI0821115A BRPI0821115A2 BR PI0821115 A2 BRPI0821115 A2 BR PI0821115A2 BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A2 BRPI0821115 A2 BR PI0821115A2
Authority
BR
Brazil
Prior art keywords
compound
aminotriazole
drug
pharmaceutical composition
derived
Prior art date
Application number
BRPI0821115-9A
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Corinna Grisostomi
Sylvia Richard-Bildstein
Sylvaine Cren
Xavier Leroy
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0821115A2 publication Critical patent/BRPI0821115A2/pt
Publication of BRPI0821115A8 publication Critical patent/BRPI0821115A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0821115A 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto BRPI0821115A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (en) 2007-12-18 2008-12-17 Aminotriazole derivatives as alx agonists

Publications (2)

Publication Number Publication Date
BRPI0821115A2 true BRPI0821115A2 (pt) 2015-06-16
BRPI0821115A8 BRPI0821115A8 (pt) 2017-12-26

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821115A BRPI0821115A8 (pt) 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Country Status (25)

Country Link
US (1) US8536209B2 (pt)
EP (1) EP2225231B1 (pt)
JP (1) JP4656674B2 (pt)
KR (1) KR101213007B1 (pt)
CN (1) CN101903378B (pt)
AR (1) AR069801A1 (pt)
AT (1) ATE520689T1 (pt)
AU (1) AU2008337097B2 (pt)
BR (1) BRPI0821115A8 (pt)
CA (1) CA2706839C (pt)
CY (1) CY1112465T1 (pt)
DK (1) DK2225231T3 (pt)
HR (1) HRP20110825T1 (pt)
IL (1) IL206399A (pt)
MA (1) MA31949B1 (pt)
MX (1) MX2010006241A (pt)
MY (1) MY153985A (pt)
NZ (1) NZ586735A (pt)
PL (1) PL2225231T3 (pt)
PT (1) PT2225231E (pt)
RU (1) RU2492167C2 (pt)
SI (1) SI2225231T1 (pt)
TW (1) TWI434685B (pt)
WO (1) WO2009077990A1 (pt)
ZA (1) ZA201005080B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
KR101724765B1 (ko) * 2009-05-18 2017-04-07 액테리온 파마슈티칼 리미티드 Alx 수용체 및/또는 fprl2 아고니스트로서의 브릿지 스피로[2.4]헵탄 유도체
JP5095035B2 (ja) * 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
KR101847672B1 (ko) 2010-12-07 2018-04-10 이도르시아 파마슈티컬스 리미티드 Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
CA2816376C (en) 2010-12-07 2018-11-20 Actelion Pharmaceuticals Ltd Oxazolyl-methylether derivatives as alx receptor agonists
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
WO2013022766A1 (en) * 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
KR20150090249A (ko) * 2012-12-03 2015-08-05 에프. 호프만-라 로슈 아게 치환된 트라이아졸 및 이미다졸 화합물
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
ES2639798T3 (es) 2013-07-18 2017-10-30 Idorsia Pharmaceuticals Ltd Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
NZ752095A (en) 2013-11-28 2022-07-01 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10525058B2 (en) 2015-05-27 2020-01-07 Kyorin Pharmaceutical Co., Ltd Urea derivative or pharmacologically acceptable salt thereof
JP2018538367A (ja) * 2015-11-24 2018-12-27 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
JP7743010B2 (ja) * 2021-03-12 2025-09-24 国立大学法人 長崎大学 ハロカルボニル化合物の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
AU2002359311A1 (en) 2001-10-26 2003-05-06 Government Of The United States Of America, As Represented By The Secretary, Department Of Health An Amyloid ss is a ligand for fpr class receptors
EP1492552A2 (en) 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
EP1692502A2 (en) 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
CN101115728B (zh) * 2004-12-13 2012-12-19 利奥制药有限公司 三唑取代的氨基二苯甲酮化合物
US8026260B2 (en) * 2005-11-03 2011-09-27 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl-motifs
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
ES2545121T3 (es) 2007-08-21 2015-09-08 Senomyx, Inc. Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
KR101724765B1 (ko) 2009-05-18 2017-04-07 액테리온 파마슈티칼 리미티드 Alx 수용체 및/또는 fprl2 아고니스트로서의 브릿지 스피로[2.4]헵탄 유도체
JP5095035B2 (ja) 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists

Also Published As

Publication number Publication date
CN101903378B (zh) 2014-03-12
HRP20110825T1 (hr) 2011-12-31
TWI434685B (zh) 2014-04-21
HK1144158A1 (en) 2011-01-28
JP2011506594A (ja) 2011-03-03
KR101213007B1 (ko) 2012-12-20
ZA201005080B (en) 2011-12-28
PT2225231E (pt) 2011-10-19
US8536209B2 (en) 2013-09-17
MX2010006241A (es) 2010-06-30
IL206399A0 (en) 2010-12-30
EP2225231A1 (en) 2010-09-08
JP4656674B2 (ja) 2011-03-23
MA31949B1 (fr) 2010-12-01
TW200932216A (en) 2009-08-01
AU2008337097A1 (en) 2009-06-25
RU2492167C2 (ru) 2013-09-10
US20100331378A1 (en) 2010-12-30
CN101903378A (zh) 2010-12-01
IL206399A (en) 2016-03-31
PL2225231T3 (pl) 2012-01-31
NZ586735A (en) 2012-06-29
RU2010129272A (ru) 2012-01-27
CY1112465T1 (el) 2015-12-09
DK2225231T3 (da) 2011-10-17
KR20100092516A (ko) 2010-08-20
AU2008337097B2 (en) 2014-03-20
WO2009077990A1 (en) 2009-06-25
BRPI0821115A8 (pt) 2017-12-26
EP2225231B1 (en) 2011-08-17
CA2706839C (en) 2015-10-20
CA2706839A1 (en) 2009-06-25
ATE520689T1 (de) 2011-09-15
AR069801A1 (es) 2010-02-17
SI2225231T1 (sl) 2011-12-30
MY153985A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0821301A2 (pt) Composto de aspirinato de isossorbida, composto carregador, composto medicamentoso, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.